Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL Behring has said that Helixate FS, its advanced recombinant factor VIII product for the treatment of hemophilia A, is now available in the US in a new 2000 international unit vial size for reducing reconstitution time by eliminating the need to mix and pool multiple vials.
Subscribe to our email newsletter
Use of Helixate FS in conjunction with CSL Behring’s new HeliTrax system can improve patient-physician communication and therapy management. The HeliTrax system combines an Internet-based encrypted database for professionals to track treatment and a wireless hand-held electronic diary for patients to log infusions and treatments with recombinant FVIII Helixate FS.
Robert Lefebvre, vice president and general manager, US commercial operations, said: “Helixate FS, with the new 2000 international unit (IU) vial, offers patients shorter infusion times, which translates into greater convenience, and will encourage compliance with prescribed treatment. The introduction of the 2000 IU vial is a solid example of CSL Behring’s ongoing commitment to advancing hemophilia therapy management and improving convenience for patients.”